Neurodegenerative diseases like Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP) form a significant public health challenge. Developing first disease modifying treatment is critical to address an increasing number of patients in an ageing population. Clinical trials in this space have been notoriously challenging with little progress over recent years. As Magnetic Resonance Imaging (MRI) plays a key part in assessing safety and efficacy of relevant drug candidates, seamless collection of high-quality MRI data is critical for successful trial design. This project validates artificial intelligence technology for the automated quality control of brain MRI data to support efficient and accurate delivery of clinical trials.
